DDInter485 DDInter1658
A very toxic anthracycline aminoglycoside antineoplastic isolated from Streptomyces peucetius and others, used in treatment of leukemia and other neoplasms.
Selpercatinib is a kinase inhibitor with enhanced specificity for RET tyrosine kinase receptors (RTKs) over other RTK classes.[A202055, A202052, L13604] Enhanced RET (Rearranged during transfection) oncogene expression is a hallmark of many cancers. Although multikinase inhibitors, including [cabozantinib], [ponatinib], [sorafenib], [sunitinib], and [vandetanib], have shown efficacy in RET-driven cancers, their lack of specificity is generally associated with substantial toxicity. Selpercatinib (LOXO-292) and pralsetinib (BLU-667) represent the first generation of specific RET RTK inhibitors for the treatment of RET-driven cancers.[A202049, A202055, A202052, L13604] Although selpercatinib is currently still under investigation in clinical trial NCT04211337, it was granted accelerated FDA approval on May 8, 2020, for specific RET-driven cancer indications. It is currently marketed under the brand name RETEVMO™ by Loxo Oncology Inc. Selpercatinib is also approved by the European Commission.
Daunorubicin {u} (Compound) resembles {v} (Compound) Doxorubicin
Daunorubicin {u} (Compound) resembles {v} (Compound) Valrubicin
Daunorubicin {u} (Compound) treats {v} (Disease) hematologic cancer
Daunorubicin {u} (Compound) binds {v} (Gene) CYP1A2
Daunorubicin {u} (Compound) upregulates {v} (Gene) GDI1
Daunorubicin {u} (Compound) is included by {v} (Pharmacologic Class) Topoisomerase Inhibitors
Daunorubicin {u} (Compound) downregulates {v} (Gene) TAF5
Daunorubicin {u} (Compound) causes {v} (Side Effect) Sickness
Daunorubicin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Metronidazole
Daunorubicin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Enoxacin
Daunorubicin (Compound) resembles Doxorubicin (Compound)
Daunorubicin (Compound) resembles Valrubicin (Compound)
Daunorubicin (Compound) treats hematologic cancer (Disease)
Daunorubicin (Compound) binds CYP1A2 (Gene)
Daunorubicin (Compound) upregulates GDI1 (Gene)
Daunorubicin (Compound) is included by Topoisomerase Inhibitors (Pharmacologic Class)
Daunorubicin (Compound) downregulates TAF5 (Gene)
Daunorubicin (Compound) causes Sickness (Side Effect)
Daunorubicin may cause a minor interaction that can limit clinical effects when taken with Metronidazole
Daunorubicin may cause a minor interaction that can limit clinical effects when taken with Enoxacin